Lung Cancer Europe/Facebook
May 21, 2025, 16:48
How Can We Build Trust in New Cancer Tools Like Liquid Biopsies? – Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn:
“How can we build trust in new cancer tools like liquid biopsies?
By involving people affected by cancer from the start.
At this week’s GUIDE.MRD General Assembly in Nice, scientific and clinical partners shared progress on how circulating tumour DNA (ctDNA) testing is being developed and benchmarked to support real-world care.
Lung Cancer Europe joined other consortium partners to help bring in the perspective of people living with lung cancer.
These blood-based liquid biopsies are already guiding treatment in some cancers and could play a bigger role in monitoring disease, detecting recurrence earlier, and informing decisions across the cancer pathway.
‘It was great to see the science and the patient perspective come together. These conversations help keep the focus on real-life impact.’ – Chiara Antoniani, LuCE Project Manager.
Special thanks to Patient Advisory Board members Merel Hennink, Stephen Rowley and Piero Rivizzigno for their thoughtful contributions—and to Ana Martins Digestive Cancers Europe and Lidewij Eva Vat (The Synergist) for their ongoing work to support meaningful patient involvement across lung, colorectal and pancreatic cancer.”
Catherine Alix-Panabières, Professor of Oncology at the Faculty of Medicine of the University of Montpellier, shared this post, adding:
“Delighted to be part of this huge consortium!”
More posts featuring Lung Cancer Europe.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 15:27